Evaluation of Temozolomide Monotherapy in Adult Patients with Non-Enhancing Diffuse Brainstem Gliomas Exhibiting Infiltrative Progression

The primary objective of the study is to evaluate the efficacy of **temozolomide** as a first-line chemotherapy treatment for adults with non-contrast-enhancing diffuse **brainstem gliomas**. These gliomas are characterized by a non-threatening infiltrative clinical and/or radiological progression. The clinical relevance of this study lies in addressing the therapeutic needs of patients with this specific subtype of brainstem gliomas, which typically exhibit a challenging progression pattern and limited treatment options.

The clinical trial involves participants diagnosed with **adult brain stem gliomas** and adults with non-contrast-enhancing diffuse brainstem gliomas exhibiting non-threatening infiltrative clinical and/or radiological progression. The study population includes both male and female subjects, with an age range that encompasses adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is designed to evaluate the efficacy of **temozolomide** as a first-line chemotherapy treatment for adults with non-contrast-enhancing diffuse brainstem gliomas, characterized by a non-threatening infiltrative clinical and/or radiological progression. This study is a Phase 4 trial, which is typically conducted to monitor the effectiveness of a treatment in a larger population and to collect information on the drug's long-term effects. The trial follows a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date was July 19, 2019, and the trial is expected to conclude by January 19, 2027.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation, including medical history, physical examination, and necessary diagnostic tests. Following successful inclusion, participants will be randomly assigned to receive either the investigational treatment or a control. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess treatment efficacy, and record any adverse events. These visits are crucial for ensuring participant safety and collecting data on the treatment's impact.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final assessment will be conducted to evaluate the overall outcomes and any long-term effects of the treatment. The expected length of participant involvement will vary depending on individual response to treatment and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial's design and procedures are structured to maintain the highest ethical standards and ensure the integrity of the collected data.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is in Phase 4, focusing on post-marketing surveillance to assess the efficacy of the intervention. The trial is scheduled to conclude on January 19, 2027, with recruitment having commenced on July 19, 2019. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will adhere to standard protocols for data collection and analysis, ensuring that the results are scientifically valid and reliable. The study will be conducted in accordance with regulatory requirements for Phase 4 trials, focusing on the long-term effects and overall benefit-risk profile of the treatment. The trial's design and execution will be aligned with the objectives of post-marketing studies, contributing to the understanding of the treatment's efficacy in a broader patient population.